Biglycan Is a Positive Modulator of BMP-2 Induced Osteoblast Differentiation

  • Yoshiyuki Mochida
  • Duenpim Parisuthiman
  • Mitsuo Yamauchi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 585)

Abstract

Development of the vertebrate skeleton is a complex process involving genes that control a series of cellular events such as proliferation, migration, mesenchymal condensations and eventually differentiation into osteoblasts and chondrocytes1. For osteoblast differentiation, an intricate and highly regulated interplay of growth factors, receptors/co-receptors, specific extracellular milieu and transcription factors is required2. Bone morphogenetic proteins (BMPs), members of the transforming growth factor-beta (TGF- ) superfamily, are multifunctional growth factors critically involved in osteoblast differentiation. The BMP functions are exerted through their interaction with specific cell surface receptors, BMP type I and II receptors, leading to the regulation of specific BMP target genes. The signaling is regulated at numerous steps at extracellular, cell surface and intracellular levels3, 4.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

7.6. References

  1. 1.
    B. R. Olsen, A. M. Reginato, and W. Wang, Bone development, Annu Rev Cell Dev Biol 16, 191–220 (2000).CrossRefGoogle Scholar
  2. 2.
    G. Xiao, R. Gopalakrishnan, D. Jiang, E. Reith, M. D. Benson, and R. T. Franceschi, Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells, J Bone Miner Res 17(1), 101–110 (2002).CrossRefGoogle Scholar
  3. 3.
    K. Miyazono, S. Maeda, and T. Imamura, BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk, Cytokine Growth Factor Rev 16(3), 251–263 (2005).CrossRefGoogle Scholar
  4. 4.
    P. ten Dijke, O. Korchynskyi, G. Valdimarsdottir, and M. J. Goumans, Controlling cell fate by bone morphogenetic protein receptors, Mol Cell Endocrinol 211(1–2), 105–113 (2003).Google Scholar
  5. 5.
    R. V. Iozzo, The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins, J Biol Chem 274(27), 18843–18846 (1999).CrossRefGoogle Scholar
  6. 6.
    L. Ameye, and M. F. Young, Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases, Glycobiology 12(9), 107R–116R (2002).CrossRefGoogle Scholar
  7. 7.
    P. Bianco, L. W. Fisher, M. F. Young, J. D. Termine, and P. G. Robey, Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues, J Histochem Cytochem 38(11), 1549–1563 (1990).Google Scholar
  8. 8.
    T. Xu, P. Bianco, L. W. Fisher, G. Longenecker, E. Smith, S. Goldstein, J. Bonadio, A. Boskey, A. M. Heegaard, B. Sommer, K. Satomura, P. Dominguez, C. Zhao, A. B. Kulkarni, P. G. Robey, and M. F. Young, Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice, Nat Genet 20(1), 78–82 (1998).CrossRefGoogle Scholar
  9. 9.
    X. D. Chen, S. Shi, T. Xu, P. G. Robey, and M. F. Young, Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells, J Bone Miner Res 17(2), 331–340 (2002).CrossRefGoogle Scholar
  10. 10.
    Y. Bi, C. H. Stuelten, T. Kilts, S. Wadhwa, R. V. Iozzo, P. G. Robey, X. D. Chen, and M. F. Young, Extracellular matrix proteoglycans control the fate of bone marrow stromal cells, J Biol Chem 280(34), 30481–30489 (2005).CrossRefGoogle Scholar
  11. 11.
    A. Hildebrand, M. Romaris, L. M. Rasmussen, D. Heinegard, D. R. Twardzik, W. A. Border, and E. Ruoslahti, Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta, Biochem J 302 (Pt 2), 527–534 (1994).Google Scholar
  12. 12.
    Y. Hayashi, C. Y. Liu, J. J. Jester, M. Hayashi, I. J. Wang, J. L. Funderburgh, S. Saika, P. J. Roughley, C. W. Kao, and W. W. Kao, Excess biglycan causes eyelid malformation by perturbing muscle development and TGF-alpha signaling, Dev Biol 277(1), 222–234 (2005).CrossRefGoogle Scholar
  13. 13.
    E. Tufvesson, and G. Westergren-Thorsson, Tumour necrosis factor-alpha interacts with biglycan and decorin, FEBS Lett 530(1–3), 124–128 (2002).CrossRefGoogle Scholar
  14. 14.
    X. D. Chen, L. W. Fisher, P. G. Robey, and M. F. Young, The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation, Faseb J 18(9), 948–958 (2004).CrossRefGoogle Scholar
  15. 15.
    M. Moreno, R. Munoz, F. Aroca, M. Labarca, E. Brandan, and J. Larrain, Biglycan is a new extracellular component of the Chordin-BMP4 signaling pathway, Embo J 24(7), 1397–1405 (2005).CrossRefGoogle Scholar
  16. 16.
    D. Parisuthiman, Y. Mochida, W. R. Duarte, and M. Yamauchi, Biglycan modulates osteoblast differentiation and matrix mineralization, J Bone Miner Res 20(10), 1878–1886 (2005).CrossRefGoogle Scholar
  17. 17.
    T. Imamura, M. Takase, A. Nishihara, E. Oeda, J. Hanai, M. Kawabata, and K. Miyazono, Smad6 inhibits signalling by the TGF-beta superfamily, Nature 389(6651), 622–626 (1997).CrossRefGoogle Scholar
  18. 18.
    T. Ebisawa, K. Tada, I. Kitajima, K. Tojo, T. K. Sampath, M. Kawabata, K. Miyazono, and T. Imamura, Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation, J Cell Sci 112 (Pt 20), 3519–3527 (1999).Google Scholar
  19. 19.
    A. Nishihara, T. Watabe, T. Imamura, and K. Miyazono, Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension, Mol Biol Cell 13(9), 3055–3063 (2002).CrossRefGoogle Scholar
  20. 20.
    K. J. Livak, and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods 25(4), 402–408 (2001).CrossRefGoogle Scholar
  21. 21.
    H. Itoh, M. Yamauchi, H. Kataoka, R. Hamasuna, N. Kitamura, and M. Koono, Genomic structure and chromosomal localization of the human hepatocyte growth factor activator inhibitor type 1 and 2 genes, Eur J Biochem 267(11), 3351–3359 (2000).CrossRefGoogle Scholar
  22. 22.
    T. Katagiri, A. Yamaguchi, M. Komaki, E. Abe, N. Takahashi, T. Ikeda, V. Rosen, J. M. Wozney, A. Fujisawa-Sehara, and T. Suda, Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage, J Cell Biol 127(6 Pt 1), 1755–1766 (1994).CrossRefGoogle Scholar
  23. 23.
    S. Maeda, M. Hayashi, S. Komiya, T. Imamura, and K. Miyazono, Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells, Embo J 23(3), 552–563 (2004).CrossRefGoogle Scholar
  24. 24.
    S. Harada, and G. A. Rodan, Control of osteoblast function and regulation of bone mass, Nature 423(6937), 349–355 (2003).CrossRefGoogle Scholar
  25. 25.
    L. A. Sabourin, and M. A. Rudnicki, The molecular regulation of myogenesis, Clin Genet 57(1), 16–25 (2000).CrossRefGoogle Scholar
  26. 26.
    J. M. Wozney, V. Rosen, A. J. Celeste, L. M. Mitsock, M. J. Whitters, R. W. Kriz, R. M. Hewick, and E. A. Wang, Novel regulators of bone formation: molecular clones and activities, Science 242(4885), 1528–1534 (1988).CrossRefGoogle Scholar
  27. 27.
    T. Kirsch, W. Sebald, and M. K. Dreyer, Crystal structure of the BMP-2-BRIA ectodomain complex, Nat Struct Biol 7(6), 492–496 (2000).CrossRefGoogle Scholar
  28. 28.
    J. Garcia Abreu, C. Coffinier, J. Larrain, M. Oelgeschlager, and E. M. De Robertis, Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems, Gene 287(1–2), 39–47 (2002).Google Scholar
  29. 29.
    S. Hartwig, M. C. Hu, C. Cella, T. Piscione, J. Filmus, and N. D. Rosenblum, Glypican-3 modulates inhibitory Bmp2-Smad signaling to control renal development in vivo, Mech Dev 122(7–8), 928–938 (2005).CrossRefGoogle Scholar
  30. 30.
    T. A. Samad, A. Rebbapragada, E. Bell, Y. Zhang, Y. Sidis, S. J. Jeong, J. A. Campagna, S. Perusini, D. A. Fabrizio, A. L. Schneyer, H. Y. Lin, A. H. Brivanlou, L. Attisano, and C. J. Woolf, DRAGON, a bone morphogenetic protein co-receptor, J Biol Chem 280(14), 14122–14129 (2005).CrossRefGoogle Scholar
  31. 31.
    H. Nishitoh, H. Ichijo, M. Kimura, T. Matsumoto, F. Makishima, A. Yamaguchi, H. Yamashita, S. Enomoto, and K. Miyazono, Identification of type I and type II serine/threonine kinase receptors for growth/differentiation factor-5, J Biol Chem 271(35), 21345–21352 (1996).CrossRefGoogle Scholar
  32. 32.
    A. Nohe, S. Hassel, M. Ehrlich, F. Neubauer, W. Sebald, Y. I. Henis, and P. Knaus, The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways, J Biol Chem 277(7), 5330–5338 (2002).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2006

Authors and Affiliations

  • Yoshiyuki Mochida
    • 1
  • Duenpim Parisuthiman
    • 1
  • Mitsuo Yamauchi
    • 1
  1. 1.CB#7455 Dental Research CenterUniversity of North Carolina at Chapel HillUSA

Personalised recommendations